Cargando…

Detection of adverse drug events in e-prescribing and administrative health data: a validation study

BACKGROUND: Administrative health data are increasingly used to detect adverse drug events (ADEs). However, the few studies evaluating diagnostic codes for ADE detection demonstrated low sensitivity, likely due to narrow code sets, physician under-recognition of ADEs, and underreporting in administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Habib, Bettina, Tamblyn, Robyn, Girard, Nadyne, Eguale, Tewodros, Huang, Allen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063436/
https://www.ncbi.nlm.nih.gov/pubmed/33892716
http://dx.doi.org/10.1186/s12913-021-06346-y
_version_ 1783681953686355968
author Habib, Bettina
Tamblyn, Robyn
Girard, Nadyne
Eguale, Tewodros
Huang, Allen
author_facet Habib, Bettina
Tamblyn, Robyn
Girard, Nadyne
Eguale, Tewodros
Huang, Allen
author_sort Habib, Bettina
collection PubMed
description BACKGROUND: Administrative health data are increasingly used to detect adverse drug events (ADEs). However, the few studies evaluating diagnostic codes for ADE detection demonstrated low sensitivity, likely due to narrow code sets, physician under-recognition of ADEs, and underreporting in administrative data. The objective of this study was to determine if combining an expanded ICD code set in administrative data with e-prescribing data improves ADE detection. METHODS: We conducted a prospective cohort study among patients newly prescribed antidepressant or antihypertensive medication in primary care and followed for 2 months. Gold standard ADEs were defined as patient-reported symptoms adjudicated as medication-related by a clinical expert. Potential ADEs in administrative data were defined as physician, ED, or hospital visits during follow-up for known adverse effects of the study medication, as identified by ICD codes. Potential ADEs in e-prescribing data were defined as study drug discontinuations or dose changes made during follow-up for safety or effectiveness reasons. RESULTS: Of 688 study participants, 445 (64.7%) were female and mean age was 64.2 (SD 13.9). The study drug for 386 (56.1%) patients was an antihypertensive, and for 302 (43.9%) an antidepressant. Using the gold standard definition, 114 (16.6%) patients experienced an ADE, with 40 (10.4%) among antihypertensive users and 74 (24.5%) among antidepressant users. The sensitivity of the expanded ICD code set was 7.0%, of e-prescribing data 9.7%, and of the two combined 14.0%. Specificities were high (86.0–95.0%). The sensitivity of the combined approach increased to 25.8% when analysis was restricted to the 27% of patients who indicated having reported symptoms to a physician. CONCLUSION: Combining an expanded diagnostic code set with e-prescribing data improves ADE detection. As few patients report symptoms to their physician, higher detection rates may be achieved by collecting patient-reported outcomes via emerging digital technologies such as patient portals and mHealth applications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-021-06346-y.
format Online
Article
Text
id pubmed-8063436
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80634362021-04-23 Detection of adverse drug events in e-prescribing and administrative health data: a validation study Habib, Bettina Tamblyn, Robyn Girard, Nadyne Eguale, Tewodros Huang, Allen BMC Health Serv Res Research Article BACKGROUND: Administrative health data are increasingly used to detect adverse drug events (ADEs). However, the few studies evaluating diagnostic codes for ADE detection demonstrated low sensitivity, likely due to narrow code sets, physician under-recognition of ADEs, and underreporting in administrative data. The objective of this study was to determine if combining an expanded ICD code set in administrative data with e-prescribing data improves ADE detection. METHODS: We conducted a prospective cohort study among patients newly prescribed antidepressant or antihypertensive medication in primary care and followed for 2 months. Gold standard ADEs were defined as patient-reported symptoms adjudicated as medication-related by a clinical expert. Potential ADEs in administrative data were defined as physician, ED, or hospital visits during follow-up for known adverse effects of the study medication, as identified by ICD codes. Potential ADEs in e-prescribing data were defined as study drug discontinuations or dose changes made during follow-up for safety or effectiveness reasons. RESULTS: Of 688 study participants, 445 (64.7%) were female and mean age was 64.2 (SD 13.9). The study drug for 386 (56.1%) patients was an antihypertensive, and for 302 (43.9%) an antidepressant. Using the gold standard definition, 114 (16.6%) patients experienced an ADE, with 40 (10.4%) among antihypertensive users and 74 (24.5%) among antidepressant users. The sensitivity of the expanded ICD code set was 7.0%, of e-prescribing data 9.7%, and of the two combined 14.0%. Specificities were high (86.0–95.0%). The sensitivity of the combined approach increased to 25.8% when analysis was restricted to the 27% of patients who indicated having reported symptoms to a physician. CONCLUSION: Combining an expanded diagnostic code set with e-prescribing data improves ADE detection. As few patients report symptoms to their physician, higher detection rates may be achieved by collecting patient-reported outcomes via emerging digital technologies such as patient portals and mHealth applications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-021-06346-y. BioMed Central 2021-04-23 /pmc/articles/PMC8063436/ /pubmed/33892716 http://dx.doi.org/10.1186/s12913-021-06346-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Habib, Bettina
Tamblyn, Robyn
Girard, Nadyne
Eguale, Tewodros
Huang, Allen
Detection of adverse drug events in e-prescribing and administrative health data: a validation study
title Detection of adverse drug events in e-prescribing and administrative health data: a validation study
title_full Detection of adverse drug events in e-prescribing and administrative health data: a validation study
title_fullStr Detection of adverse drug events in e-prescribing and administrative health data: a validation study
title_full_unstemmed Detection of adverse drug events in e-prescribing and administrative health data: a validation study
title_short Detection of adverse drug events in e-prescribing and administrative health data: a validation study
title_sort detection of adverse drug events in e-prescribing and administrative health data: a validation study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063436/
https://www.ncbi.nlm.nih.gov/pubmed/33892716
http://dx.doi.org/10.1186/s12913-021-06346-y
work_keys_str_mv AT habibbettina detectionofadversedrugeventsineprescribingandadministrativehealthdataavalidationstudy
AT tamblynrobyn detectionofadversedrugeventsineprescribingandadministrativehealthdataavalidationstudy
AT girardnadyne detectionofadversedrugeventsineprescribingandadministrativehealthdataavalidationstudy
AT egualetewodros detectionofadversedrugeventsineprescribingandadministrativehealthdataavalidationstudy
AT huangallen detectionofadversedrugeventsineprescribingandadministrativehealthdataavalidationstudy